Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers.

Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers.

Bibliographic Details
Main Authors:	Hugosson, J, Lilja, H, Lodding, P, Pihl, C
Format:	Journal article
Language:	English
Published:	2001

Similar Items

The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
by: Zackrisson, B, et al.
Published: (2004)

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
by: Zackrisson, B, et al.
Published: (2003)

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
by: Hugosson, J, et al.
Published: (2003)

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
by: Hugosson, J, et al.
Published: (2004)

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
by: Hugosson, J, et al.
Published: (2003)

Defining surrogate endpoints for clinical trials in severe Falciparum malaria.
by: Jeeyapant, A, et al.
Published: (2017)

Significance of biomarkers and surrogate endpoints in preclinical and clinical trials
by: Ilić Katarina, et al.
Published: (2007-01-01)

Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial.
by: Aus, G, et al.
Published: (2007)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
by: Aus, G, et al.
Published: (2004)

The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status
by: Heather Poad, et al.
Published: (2022-11-01)

Mortality results from the Goteborg randomised population-based prostate-cancer screening trial.
by: Hugosson, J, et al.
Published: (2010)

Biomarkers and surrogate endpoints.
by: Aronson, J
Published: (2005)

Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden.
by: Hugosson, J, et al.
Published: (2000)

Erratum: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section (International Journal of Cancer (2007) 120, (170-174))
by: Khatami, A, et al.
Published: (2007)

Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
by: Aus, G, et al.
Published: (2003)

Screening for prostate cancer.
by: Carlsson, S, et al.
Published: (2012)

Biomarkers and Surrogate Endpoints in Monitoring Therapeutic Interventions
by: Aronson, J
Published: (2008)

Screening for prostate cancer: To the editor
by: Carlsson, S, et al.
Published: (2012)

Simulation studies of surrogate endpoint validation using single trial and multitrial statistical approaches.
by: Lassere, M, et al.
Published: (2007)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
by: Vickers, A, et al.
Published: (2010)

Quetiapine-Related Deaths: In Search of a Surrogate Endpoint
by: Ivan Šoša
Published: (2024-01-01)

Surrogate endpoints in trials: a call for better reporting
by: Oriana Ciani, et al.
Published: (2022-12-01)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
by: Vickers, A, et al.
Published: (2008)

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE
by: Manyara, AM, et al.
Published: (2022)

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE
by: Martin Offringa, et al.
Published: (2022-10-01)

Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials
by: An Wang, et al.
Published: (2023-06-01)

Establishing surrogate kidney endpoints for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes
by: Mackay, M, et al.
Published: (2019)

Corrigendum: Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials
by: An Wang, et al.
Published: (2024-02-01)

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section.
by: Khatami, A, et al.
Published: (2007)

Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
by: Lassere, M, et al.
Published: (2007)

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials
by: Ciani, O, et al.
Published: (2023)

Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers
by: Anthony Muchai Manyara, et al.
Published: (2022-01-01)

A call for better reporting of trials using surrogate primary endpoints
by: Anthony Muchai Manyara, et al.
Published: (2022-01-01)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
by: Becker, C, et al.
Published: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
by: Becker, C, et al.
Published: (2003)

Defining information fractions in group sequential clinical trials with multiple endpoints
by: Tu Xu, et al.
Published: (2018-06-01)

Combining Correlated Outcomes and Surrogate Endpoints in a Network Meta-Analysis of Colorectal Cancer Treatments
by: Tung Hoang, et al.
Published: (2020-09-01)

Simple Methods for Evaluating 4 Types of Biomarkers: Surrogate Endpoint, Prognostic, Predictive, and Cancer Screening
by: Stuart G Baker, et al.
Published: (2020-07-01)

PB1947: A META-ANALYTIC ENDPOINT VALIDATION OF SURROGATES USED IN CLINICAL TRIALS EVALUATING THE EFFICACY OF THERAPIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
by: Nasim Bahar, et al.
Published: (2023-08-01)

Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
by: Bruun, L, et al.
Published: (2005)